Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001753926-25-000149
Filing Date
2025-01-27
Accepted
2025-01-27 17:28:30
Documents
48
Period of Report
2023-11-30

Document Format Files

Seq Description Document Type Size
1 10-Q g084662_10q.htm   iXBRL 10-Q 655371
2 EXHIBIT 31.1 g084662_ex31-1.htm EX-31.1 14791
3 EXHIBIT 32.1 g084662_ex32-1.htm EX-32.1 5128
  Complete submission text file 0001753926-25-000149.txt   3624766

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ivbt-20231130.xsd EX-101.SCH 33621
5 XBRL CALCULATION FILE ivbt-20231130_cal.xml EX-101.CAL 37458
6 XBRL DEFINITION FILE ivbt-20231130_def.xml EX-101.DEF 132492
7 XBRL LABEL FILE ivbt-20231130_lab.xml EX-101.LAB 270549
8 XBRL PRESENTATION FILE ivbt-20231130_pre.xml EX-101.PRE 197665
51 EXTRACTED XBRL INSTANCE DOCUMENT g084662_10q_htm.xml XML 382038
Mailing Address 179 RTE 46W, SUITE 15 #147 ROCKAWAY NJ 07866
Business Address 179 RTE 46W, SUITE 15 #147 ROCKAWAY NJ 07866 929-459-4966
Innovation1 Biotech Inc. (Filer) CIK: 0001629205 (see all company filings)

EIN.: 822275255 | State of Incorp.: NV | Fiscal Year End: 0831
Type: 10-Q | Act: 34 | File No.: 000-55852 | Film No.: 25560200
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)